Therapeutic Antibodies

#Covid-19 #Healthcare #Monoclonal antibodies

First monoclonal antibody treatment for Covid-19 approved for UK 

Following a thorough review of evidence carried out by the Medicines and Healthcare products Regulatory Agency (MHRA) and recommendation by the Commission on Human Medicines (CHM), the UK government’s independent expert scientific advisory body, the MHRA has approved Ronapreve as the first monoclonal antibody combination product indicated for use in the… Read More

#Covid-19 #News #Trending News

#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies

Monoclonal antibody prevents malaria in NIH trial 

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health (NIH) safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria… Read More

#News #Trending News

#Antibodies #Biology #Genes

Sino Biological listed on the Shenzhen Stock Exchange 

Sino Biological has announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext. A total of 17 million shares were issued for a total of ¥4.98 billion (US$770 million) raised during this initial public offering.   Sino Biological says the listing is an important milestone in its strategic… Read More

#Business & Investment #News

#Biologics #Biology #Data #Genetics / genomics #RNA #Therapeutics

Starting line: focus on Canadian start-ups

DDW Editor Lu Rahman selects three Canadian start-ups worth watching: AbCellera Biologics, BlueRock Therapeutics and Deep Genomics. AbCellera Biologics AbCellera Biologics was founded in 2012 as a spin out from the University of British Colombia. The company searches, decodes, and analyses natural immune systems to find antibodies that can be… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion #Start-up Zone

#Biologics #Cancer research #Drug development #mRNA #R&D

What it means for drug discovery to partner with a CDMO

Following the announcement by Samsung Biologics that it planned to add mRNA vaccine drug substance manufacturing services to its offering, DDW’s Megan Thomas spoke to Seahee Kim about what this means for both business and drug development.   MT: As a CDMO, Samsung Biologics can offer both development and manufacturing… Read More

#Business & Investment #Cancer Research #Editor's Choice #Exclusive Content #News

Business agreement
#Antibodies #Bioproduction #Flow Cytometry #Life sciences #Proteogenomics #Reagents

PerkinElmer to acquire BioLegend

PerkinElmer has entered into an agreement to acquire BioLegend, provider of life science antibodies and reagents, for approximately US$5.25 billion. The transaction will be the largest in PerkinElmer’s history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing… Read More

#News

#Antibodies #Biopharmaceuticals #Biotherapeutics #Covid-19 #SARS-CoV-2

Helping Indian biotherapeutic companies advance novel therapeutics

Fusion Antibodies and BioTickle, its distributor in India, are providing local biopharmaceutical organisations with access to biopharmaceutical development capabilities. Since the emergence of Covid-19, Fusion Antibodies has contributed resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown positive profiles… Read More

#News

#AI / data analytics / healthtech / informatics #Biologics #Cell culture #Mass spectrometry / NMR

New data integrations to accelerate bioprocess data insights

908 Devices has announced two data analysis partnerships to integrate with the REBEL, its first at-line fresh and spent cell media analyser for bioprocess labs. With the integration of leading data exploratory tool Sartorius’ SIMCA and Securecell’s Lucullus Process Information Management System (PIMS), users can turn REBEL data into deeper… Read More

#News

#Antibodies #Complex medicines #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug targets #Life sciences

Financial benefit of complex medicines to UK life sciences

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK… Read More

#News

#Antibodies #AstraZeneca #Biomedical research #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccines

Covid antibody levels vary according to vaccine type

Two doses of the Oxford-AstraZeneca Covid-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains. These laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre are published… Read More

#Covid-19 #News #Trending News

#Antibodies #Biotherapeutics #Clinical trial

IONTAS collaboration with F-star enters clinical trial

F-star Therapeutics has dosed the first patients in a Phase I clinical trial, with FS222, a CD137/PD-L1 bispecific antibody. IONTAS applied its proprietary technology to generate a component utilised within FS222, which was subsequently licenced to F-star. António Parada, CEO at IONTAS, commented: “We are delighted with the progress of… Read More

#News

#Biologics #Biopharmaceuticals #Drug delivery #Drug development #Events #Process analytical technology

Agilent completes the InfinityLab Bio LC portfolio

Agilent Technologies has launched three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release has been described by Agilent as central to its portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that integrate with Agilent OpenLab and MassHunter software, and… Read More

#News

#Biologics #Cell and gene therapy #Drug development

Yposkesi launches construction of its second commercial bioproduction site

Yposkesi, a Contract Development and Manufacturing Organisation (CDMO) specialising in cell and gene therapies, has announced the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat… Read More

#News

#Antibodies #Biopharmaceutical #Collaboration #Sitting Down With

Antibody engineering: the importance of collaboration and successful partnerships

The latest DDW Sponsored Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. Listen to hear Mathur discuss the company philosophy, how the pandemic has affected… Read More

#Podcasts

#Antibodies #Biopharmaceutical #Collaboration

Antibody engineering: the importance of collaboration – podcast

The latest DDW Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why… Read More

#Editor's Choice #News

#Antibodies #Drug development #Life sciences

Picking the right custom antibody provider

Selecting the right custom antibody provider for a project is an important decision. It can mean the difference between a breakthrough or failure. It is therefore important where and how antibodies are made. With this infographic, available for free download, you will learn what sets Fortis Life Science’s Bethyl… Read More

#Editor's Choice #News